{
 "name": "TLC-KY",
 "slug": "tw-7924",
 "aliases": [
  "TLC BioSciences Corp.",
  "TLC-KY",
  "7924"
 ],
 "ticker": "7924",
 "industry": "生技醫療業",
 "website": "https://www.tlcbio.com",
 "summary": "TLC-KY（7924）是興櫃的生技醫療類股公司，2021 年成立，2026 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "TLC BioSciences Corp.",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "TLC-KY",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2026-06-26",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2021-06-29",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "洪基隆",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "葉志鴻",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 1335606870,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.tlcbio.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：TLC599（dexamethasone sodium phosphate）",
   "value": "膝骨關節炎疼痛｜第三期多區域臨床試驗推進中｜美國、日本",
   "unit": "",
   "as_of": "2026-10-05",
   "source": "https://www.tlcbio.com/en/news/detail/20261005",
   "note": "公司公告說明TLC599為BioSeizer長效型關節腔注射劑；日本第二期PK試驗已完成。"
  },
  {
   "claim": "授權合作：TLC599",
   "value": "日本臟器製藥株式會社（Nippon Zoki Pharmaceutical）｜日本｜2026-10-05",
   "unit": "",
   "as_of": "2026-10-05",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢7924、115年度、全年度、序號1。發言日期2026-10-05 15:28:33；主旨：代子公司台灣微脂體股份有限公司公告與日本臟器製藥株式會社簽訂TLC599日本地區獨家授權契約。契約日期2026-10-05；獨家開發及商業化權利。公告的2.03億美元為簽約金與各類里程碑合計上限，不能拆成個別金額，也不等於已收款，故未填各金額fact。"
  },
  {
   "claim": "管線：TLC590（ropivacaine）",
   "value": "術後疼痛｜美國第三期樞紐試驗頂線結果達主要療效指標｜美國",
   "unit": "",
   "as_of": "2026-10-19",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢7924、115年度、全年度、序號7。發言日期2026-10-19 18:21:52；主旨：公告本公司長效術後止痛新藥TLC590第三期臨床試驗初步分析結果達成主要療效指標，次要療效指標相較脂質體佈匹卡因達統計顯著差異。尚在完整分析與上市申請準備，未核准上市。"
  },
  {
   "claim": "催化劑：TLC599",
   "value": "日本第二期PK試驗完整數據分析完成並公告｜2026-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-19",
   "source": "https://www.tlcbio.com/en/news/detail/20260819a",
   "note": "官方公告原文Full trial data analysis ... expected ... fourth quarter of 2026。尚查無已公告數據之後續一手文件。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-7924.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}